Ayurveda Deserves Respect But Does It Deserve a Pass on Proof
Ayurveda commands respect because it is not a fad. It is one of India’s major knowledge traditions, rooted in texts, practice, institutions, and millions of lived choices. That respect is real. It still cannot answer the question regulators, courts, doctors, and patients must ask when a product claims to treat disease: where is the proof?
That distinction matters because Ayurveda is no longer only a household practice or a traditional clinical system. It is also a modern market. Products move through supply chains, appear in advertisements, carry labels, seek certificates, and make claims in a crowded health economy. Once a product promises to cure, prevent, or treat a serious disease, reverence is not enough. Evidence, safety testing, and truthful advertising become non-negotiable.
The Coronil controversy brought this conflict into public view. So did the debate around Rule 170 of AYUSH advertising rules, concerns about heavy metals in some rasa shastra preparations, and the weak design of many clinical trials in the field. Read together, these episodes show the same pattern: tradition has public value, but public health needs proof.
This article is informational only and is not medical or legal advice.
Coronil showed why health claims need more than confidence
In June 2020, during the first year of the COVID-19 pandemic, Patanjali launched Coronil with a claim that it could cure COVID-19. The timing matters. Fear was widespread, treatments were uncertain, and public demand for protection was intense. In such a setting, a cure claim carries unusual force. It can influence whether people seek testing, isolation, vaccination, hospital care, or other medical help.
The Ministry of AYUSH later told the Supreme Court that it had issued a notice immediately and had asked the company to stop advertising such claims until the product was evaluated. That response recognised a basic regulatory principle: a health claim must be checked before it is promoted, especially during a public health emergency.
The company pointed to a certificate from the Central Drugs Standard Control Organisation, or CDSCO, issued under the World Health Organization certification scheme. Critics said this was presented in a way that suggested WHO certification. The Indian Medical Association, or IMA, called that claim a “blatant lie”. The distinction may sound technical, but it is central to health communication.
A certificate issued under a WHO-linked scheme is not the same as the WHO certifying a product as a cure. To a layperson, the difference can easily disappear. Regulators and courts treat that confusion seriously because medical claims depend on trust. If a certificate is framed in a way that gives the public a false impression, the problem is not an academic one. It can change behaviour.
The issue did not end in 2020. In 2024, the Supreme Court heard an IMA petition that cited around 30 allegedly misleading advertisements by Patanjali. The Court rejected the company’s apologies and said contempt proceedings would be taken to their logical end. The legal message was clear: once a court has issued directions on misleading medical advertising, apology alone may not undo repeated non-compliance.
The Coronil episode is often framed as a clash between allopathy and Ayurveda. That framing misses the harder question. The point is not whether Ayurvedic products may ever help. The point is whether a company can make strong disease-cure claims without evidence that meets the claim. In health regulation, the strength of the claim should match the strength of the proof.
A mild wellness statement and a cure claim are not the same. A product that says it supports general wellbeing raises one kind of regulatory concern. A product that says it cures COVID-19 raises a much higher one. The second claim needs clinical evidence, clear endpoints, careful trial design, safety data, and transparent communication to the public.
That is why the Coronil matter still matters beyond one company. It sits at the intersection of Ayurveda regulation India, Coronil Patanjali Supreme Court, Rule 170 AYUSH advertisements, rasa shastra heavy metals, Ayurveda clinical trials. Each phrase points to the same core issue: traditional medicine cannot be regulated only through cultural pride or market confidence. It needs a public evidence standard.
Rule 170 exposed the weak spine of advertising control
Advertising rules are not minor paperwork. They decide what companies can tell people before those people spend money, delay care, or give a product to a child, an elderly parent, or a patient with a serious illness.
Rule 170 required prior approval for advertisements of Ayurvedic, Siddha, and Unani medicines. In practical terms, it gave regulators a tool to check claims before they reached the public. That kind of prior scrutiny is especially relevant in health because harm can occur before a misleading claim is corrected. By the time a regulator acts, consumers may already have bought the product or relied on it.
The regulatory trail around Rule 170 has been striking.
Date | Development | Why it mattered |
August 2023 | The Ministry of AYUSH asked states not to act under Rule 170 | This weakened the use of prior approval for Ayurvedic medicine advertisements |
July 2024 | The ministry omitted Rule 170 outright | The formal basis for that prior approval requirement was removed |
Later in 2024 | The Supreme Court first stayed the omission, then later vacated its stay | Rule 170 remained omitted after the stay was vacated |
For law and regulation students, the episode raises a familiar question: what happens when the executive branch relaxes an enforcement tool while courts are dealing with misleading medical claims? For health policy readers, the question is sharper: what replaces that tool?
If Rule 170 disappears, the system must still control false or exaggerated medical advertising. That can happen through other laws, drug rules, consumer protection law, contempt proceedings, or post-publication enforcement. Yet post-publication action is often slower. It asks regulators to chase claims after they have already circulated.
This is why prior approval matters in health markets. It does not prove that every approved advertisement is scientifically sound. It does not remove the need for later enforcement. But it can create friction before a claim becomes public. It asks a company to support a claim before people act on it.
The removal of a prior approval rule may be defended on the ground that it reduces administrative burden or avoids arbitrary state-level control. Those are not trivial concerns. Over-regulation can block legitimate products, create delay, and invite inconsistent enforcement. The answer, though, is not to leave the field under-policed. The answer is clearer standards, transparent timelines, trained reviewers, and penalties that companies cannot treat as a cost of doing business.
A workable advertising regime should do at least five things:
Define the difference between wellness claims, treatment claims, and cure claims.
Require stronger evidence for stronger medical claims.
Make certificates and approvals easy to understand for consumers.
Penalise repeat violations more heavily than first-time errors.
Publish enough information for public scrutiny.
The Coronil case shows why this matters. If an advertisement implies endorsement by a global health body, the public may treat that as a guarantee. If a product claims to cure a serious infection, the public may treat it as an alternative to tested care. Advertising law is one of the first lines of defence against that risk.
Rasa shastra raises a safety question that culture cannot settle
The evidence debate is not only about whether an Ayurvedic product works. It is also about whether it is safe.
Rasa shastra is a branch of Ayurveda that uses preparations combining herbs with metals and minerals, including substances such as mercury and lead. Practitioners may argue that traditional purification and processing methods change the nature of these substances and make them safe when properly prepared. That claim cannot be accepted or rejected by instinct. It has to be tested.
A widely cited warning came from a 2008 study in JAMA. Researchers bought 193 Ayurvedic products online and tested them for lead, mercury, and arsenic. About 21 per cent exceeded daily intake limits for at least one of these metals. The study also reported that some Indian rasa shastra products could deliver 100 to 10,000 times acceptable levels.
That finding should be read carefully. The sample came from online sales. It was not a census of all Ayurvedic products in India. It did not prove that every rasa shastra medicine is unsafe. It also did not show that every Indian pharmacy sells contaminated products.
Still, it was a serious warning. A one-in-five signal in a tested online sample is not a small concern, especially when the substances involved can damage the nervous system, kidneys, blood, and other organs. Heavy metal toxicity can be slow, confusing, and hard to link to a product unless doctors ask the right questions and laboratories test for it.
India does have labelling rules. Rule 161 requires labels for certain Ayurvedic, Siddha, and Unani medicines to disclose the presence of specified ingredients, including substances of concern. Labelling is a necessary step. It tells consumers and clinicians what they may be dealing with.
Yet labelling alone does not solve the safety problem. A label helps only if it is complete, correct, readable, and backed by testing. Critics point to weak testing and uneven enforcement. Those concerns are plausible because India’s market is vast and diverse. Products range from small local preparations to large branded lines sold across states and online platforms.
For patients and families, the practical point is simple: “natural” does not always mean risk-free. A product can come from a traditional system and still contain pharmacologically active substances. It may interact with other medicines. It may be unsafe in pregnancy, kidney disease, liver disease, or childhood. It may be safe only at certain doses or after certain processing steps.
For regulators, the question is broader. How should India assess products that openly include metals as part of their formulation? A serious safety regime would need:
Batch-level testing for heavy metals where relevant.
Clear limits based on credible toxicology.
Publicly inspectable labelling requirements.
Traceability for manufacturers and suppliers.
Reporting systems for adverse events.
Penalties for products that exceed safety limits or hide ingredients.
This does not require hostility to Ayurveda. It requires taking Ayurvedic medicines seriously enough to test them like medicines. If a preparation is powerful enough to treat disease, it is powerful enough to cause harm when poorly made, falsely labelled, or wrongly used.
The trial problem is real, but it is not an argument against research
Evidence is the other major gap. The US National Institutes of Health has noted that most Ayurvedic clinical trials have been small, have design problems, or lack proper control groups. That does not prove Ayurveda is ineffective. It means many claims are not yet supported by the kind of evidence that modern health systems need before recommending a treatment at scale.
A weak trial can mislead in both directions. It can make an ineffective product look useful. It can also fail to detect a real benefit because it is too small, poorly controlled, or badly measured. This is why better trials help everyone, including credible Ayurvedic practitioners.
A strong trial does not have to erase Ayurvedic theory. It can respect the logic of a traditional system while still asking clear empirical questions. For example, researchers can study a defined formulation, a defined patient group, a defined dose, and a defined outcome. They can also test whole-system approaches where that is clinically appropriate, as long as the design is transparent.
The challenge is that many Ayurvedic interventions are personalised. Practitioners may tailor treatment according to constitution, symptoms, diet, season, and other factors. Standard randomised controlled trials often prefer uniform interventions. That creates tension, but not impossibility.
Researchers can use designs that fit the intervention better, such as:
Pragmatic trials that study care in real-world settings.
Randomised trials with clear but flexible protocols.
Comparative effectiveness trials against standard care or add-on care.
Safety studies with long-term follow-up.
Registries that track outcomes and adverse events over time.
The key is not to demand one rigid study model for every question. The key is to match the study design to the claim. A product claiming to cure an acute viral infection needs direct evidence for that infection. A treatment claiming to reduce chronic pain needs validated pain and function measures. A medicine claiming to improve metabolic markers needs lab outcomes, follow-up, and careful monitoring.
Evidence standards protect traditional systems from overclaiming by their own commercial actors. Without quality evidence, the most aggressive advertisers can dominate the public image of Ayurveda. The quiet clinician, the cautious researcher, and the responsible manufacturer are then pulled into the same credibility crisis.
That is the hidden cost of weak evidence. It does not merely expose patients to risk. It damages the reputation of the tradition itself.
Respect and scrutiny are not opposites
Defenders of Ayurveda often argue that denigrating it causes harm. That concern should not be dismissed. India’s medical history includes colonial dismissal of indigenous knowledge, unequal funding, and a tendency to equate Western biomedical categories with scientific truth itself. A respectful public debate should not caricature Ayurveda as superstition.
At the same time, criticism of a claim is not the same as contempt for a tradition. Asking whether Coronil could cure COVID-19 is not an attack on Charaka, Sushruta, or India’s intellectual history. Asking whether a rasa shastra product contains unsafe levels of lead is not cultural hostility. Asking whether trials are well designed is not a demand that Ayurveda stop existing.
The sharper ethical question is about patients. People should be free to choose. But choice only means something when people have information that is accurate, complete, and understandable. A consumer cannot make a meaningful choice if an advertisement exaggerates benefits, hides uncertainty, or blurs the difference between regulatory paperwork and scientific endorsement.
This applies across medical systems. A pharmaceutical company should not be allowed to overstate trial results. A hospital should not advertise unrealistic outcomes. A supplement manufacturer should not imply disease cures without evidence. An Ayurvedic company should not get a lower standard because it invokes tradition.
Equal respect means equal accountability.
A sensible policy position would avoid two extremes. One extreme treats all traditional medicine as invalid until it is translated into a biomedical frame. The other treats tradition as self-validating and places the burden on critics to prove harm after products enter the market. Neither approach serves patients well.
A better standard would ask three questions before strong claims reach the public:
What exactly is being claimed?
A general wellness claim and a cure claim cannot be treated alike.
What evidence supports that claim?
The evidence should fit the disease, product, dose, and patient group.
What are the known and plausible risks?
Safety testing, labelling, and adverse event tracking should be part of the approval and monitoring process.
This framework does not single out Ayurveda. It applies the same public health logic to any intervention that seeks public trust.
India needs a stronger evidence compact for traditional medicine
The policy challenge is not whether Ayurveda should be protected or punished. It is how India can build a system where valuable traditional knowledge is studied, safe products are trusted, misleading claims are stopped early, and patients are not left to decode legal and scientific signals on their own.
That requires a compact between regulators, industry, practitioners, researchers, and the public.
Regulators need clear rules and the will to enforce them. If a company repeatedly makes misleading claims, penalties should be visible and meaningful. If a rule such as prior approval for advertisements is removed, an equally effective mechanism should fill the gap. Courts should not have to become the routine advertising regulator for health products.
Industry needs to stop treating cultural legitimacy as a substitute for clinical evidence. Large companies have the resources to fund better studies, improve safety testing, and publish clearer data. If they want national and global credibility, they should welcome higher standards rather than resist them.
Researchers need funding and methods that can test Ayurvedic interventions fairly. Poorly designed trials waste money and leave the field stuck in the same argument. Better trials may confirm some uses, reject others, and refine many. That is how health knowledge grows.
Practitioners need space to contribute clinical insight without being reduced to marketing claims. Experienced Ayurvedic clinicians may know which questions are worth studying, which formulations are misused, and which patient groups need caution. Their knowledge should inform research design, not replace it.
Patients need plain information. Labels should disclose ingredients. Advertisements should not overstate claims. Certificates should not be presented in a way that misleads. Safety warnings should be readable. Doctors should ask patients about traditional medicines without judgement, because silence can hide interactions and toxicity.
The Coronil litigation, Rule 170 controversy, heavy metal concerns, and weak trial base are not separate stories. They are signs of the same unfinished task. India has a living tradition with public trust, but its regulatory and evidence systems have not fully caught up with the size and force of the market built around that tradition.
Respect is the starting point. Proof is the safeguard. If Ayurveda matters, it deserves the discipline of good science, honest labels, careful trials, and firm action against misleading claims. Tradition should not receive a pass on proof. It should receive the benefit of being tested well.
